Recombinant Humanized Monoclonal Antibody MIL62 Injection Clinical Trials

1 actively recruiting trial

Also known as: MIL62

Pipeline

Phase 1/2: 1

Top Sponsors

Beijing Mabworks Biotech Co., Ltd.1

Indications

Follicular Lymphoma and Marginal Zone Lymphoma1
Cancer1

Other1 trial

MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.